Arcalyst (rilonacept) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

MEMBER INFORMATION				
LAST NAME:	FIRST NAME:			
PHONE NUMBER:	DATE OF BIRTH:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
PATIENT INSURANCE ID NUMBER:				
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: <u>PRIMETHERAPEUTICS.COM/NOPP</u>

PRESCRIBER INFORMATION				
LAST NAME:	FIRST NAME:			
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:			
NPI NUMBER:	DEA NUMBER:			
PHONE NUMBER:	FAX NUMBER:			
STREET ADDRESS:				
CITY:	STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:			

MEDICATION OR MEDICAL DISPENSING INFORMATION					
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
NEW THERAPY		IF RENEWAL: DATE THERAPY	INITIATED:		
DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.



Arcalyst (rilonacept) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO		
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR		
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:		
2. LIST DIAGNOSES:		ICD-10:		
Familial Cold Auto-inflammatory Syndron	ne (FCAS)			
Muckle-Wells syndrome (MWS)				
Deficiency of interleukin-1 receptor a	- · ·			
Other DiagnosisICD-10 Co	ode(s):			
3. REQUIRED CLINICAL INFORMATION: PRIOR AUTHORIZATION.	PLEASE PROVIDE ALL RELEVANT CLINIC	AL INFORMATION TO SUPPORT A		
Will the drug be used in conjunction w	vith a clinical trial? 🗆 Yes 🗆 No			
win the drug be used in conjunction w				
Is prescriber a rheumatologist or imm	unologist? 🗆 Yes 🗆 No			
Does patient have genetic evidence of an <i>NLRP3</i> mutation? Yes No Please submit documentation. 				
Does patient have signs and symptoms of FCAS such as recurrent, intermittent fever and rash that were exacerbated by exposure to generalized cool ambient temperature? Yes No Please submit documentation. 				
Does patient have signs and symptoms of MWS such as chronic fever and rash of waxing and waning intensity, sometimes exacerbated by exposure to generalized cool ambient temperature? Yes Do Please submit documentation.				
For diagnosis of deficiency of interleukin-1 receptor antagonist(DIRA), answer the following: Does patient have lab confirmed homozygous mutations of <i>IL1RN</i> causing deficiency of interleukin-1 receptor antagonist? Yes No Please submit documentation.				
Does patient exhibit clinical manifestations of DIRA such as diffuse pustular rash, sterile osteomyelitis, and/or periostitis with articular pain? Yes No Please submit documentation.				
Does patient have any other rheumatic disease or major chronic infectious/inflammatory/immunologic disease such as inflammatory bowel disease, psoriatic arthritis, spondyloarthropathy, system lupus erythrematosus(SLE)? Yes No Please submit documentation.				
Does patient require maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)? Yes No 				
Has patient had prior use with non-steroidal anti-inflammatories, methotrexate, and/or corticosteroids? 🗆 Yes 🗆 No Please submit documentation.				
Has patient had prior use with at least 3 months of Kineret(anakinra)? 🗆 Yes 🗆 No Please submit documentation.				



Arcalyst (rilonacept) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit

Phone: 877-228-7909 Fax: 800-424-7640

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640 MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

